Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A | P20648 | 10/20 | 0.39 |
| ▸ | ATP4B | P51164 | 10/20 | 0.39 |
| ▸ | ABL1 | P00519 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | XIAP | P98170 | 1/20 | 0.34 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zaltidine SCHEMBL10340281 | 0.99 | ATP4A (0.38) | ATP4AATP4BABL1MEN1ALDH1A1 | |
| Zaltidine SCHEMBL9371241 | 0.99 | ATP4A (0.38) | ATP4AATP4BABL1MEN1ALDH1A1 | |
| Zaltidine SCHEMBL10340389 | 0.99 | ATP4A (0.38) | ATP4AATP4BABL1MEN1ALDH1A1 | |
| SCHEMBL10859494 | 0.84 | ATP4A (0.35) | ATP4AATP4BABL1MEN1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL10972462 | 0.83 | MAPT (0.36) | ATP4AATP4BABL1MEN1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL10978743 | 0.83 | MAPT (0.36) | ATP4AATP4BABL1MEN1ALDH1A1 | |
| SCHEMBL10858261 | 0.81 | ATP4A (0.35) | ATP4AATP4BABL1RAB9A | |
| Bromide SCHEMBL10859506 | 0.80 | ATP4A (0.35) | ATP4AATP4BABL1RAB9A | |
| Hydrochloric Acid SCHEMBL10974350 | 0.79 | TYR (0.36) | ATP4AATP4BABL1MEN1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL11032190 | 0.79 | ATP4A (0.38) | ATP4AATP4BABL1MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | claimed |
| EP-2010508-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | claimed |
| WO-2007120096-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | claimed |
| EP-0703782-A1 | H2-ANTAGONISTS AS IMMUNE STIMULANTS IN BACTERIAL INFECTIONS OF CATTLE OR SWINE | PFIZER INC. (US) | 1996-04-03 | — | — | EP | claimed |
| WO-1994028898-A1 | H2-ANTAGONISTS AS IMMUNE STIMULANTS IN BACTERIAL INFECTIONS OF CATTLE OR SWINE | PFIZER INC. (US) | 1994-12-22 | — | — | WO | claimed |
| EP-0178121-B1 | IMPROVED FORMULATION OF ANTIINFLAMMATORY DRUGS | PFIZER INC. (US) | 1990-06-13 | — | — | EP | claimed |
| EP-0178822-B1 | 2-GUANIDINO-4-(2-METHYL-4-IMIDAZOLYL)THIAZOLES IN THE TREATMENT OF RHEUMATOID ARTHRITIS | PFIZER INC. (US) | 1990-01-17 | — | — | EP | claimed |
| EP-0138464-B1 | 2-AMINO-5-HYDROXY-4-METHYLPYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1989-11-15 | — | — | EP | claimed |
| US-4673677-A | 2-AMINO-5-HYDROXY-4-METHYLPYRIMIDINE | PFIZER INC. (US) | 1987-06-16 | — | — | US | claimed |
| US-4636498-A | OXICAMS, ANTIULCER, ANTISECRETORY 2-GUANIDINO-4-(4-IMIDAZOLYL) THIAZOLES | PFIZER INC. (US) | 1987-01-13 | — | — | US | claimed |
| US-4591595-A | 2-guanidino-4-(2-methyl-4-imidazolyl)thiazoles in the treatment of rheumatoid arthritis | PFIZER INC. (US) | 1986-05-27 | — | — | US | claimed |
| EP-0178822-A2 | 2-Guanidino-4-(2-methyl-4-imidazolyl)thiazoles in the treatment of rheumatoid arthritis | PFIZER INC. (US) | 1986-04-23 | — | — | EP | claimed |
| EP-0178121-A2 | Improved formulation of antiinflammatory drugs | PFIZER INC. (US) | 1986-04-16 | — | — | EP | claimed |
| EP-0178124-A1 | Improved antiinflammatory salts of piroxicam | PFIZER INC. (US) | 1986-04-16 | — | — | EP | claimed |
| US-4567179-A | Antiinflammatory salts of piroxicam | PFIZER, INC. (US) | 1986-01-28 | — | — | US | claimed |
| US-4554276-A | ENZYME INHIBITORS, ANTIULCER AGENTS | PFIZER INC. (US) | 1985-11-19 | — | — | US | claimed |
| EP-0138464-A2 | 2-Amino-5-hydroxy-4-methylpyrimidine derivatives | PFIZER INC. (US) | 1985-04-24 | — | — | EP | claimed |
| EP-0050458-B1 | 2-GUANIDINO-4-HETEROARYLTHIAZOLES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PFIZER INC. (US) | 1985-01-02 | — | — | EP | claimed |
| EP-0050458-A2 | 2-Guanidino-4-heteroarylthiazoles and pharmaceutical compositions containing them | PFIZER INC. (US) | 1982-04-28 | — | — | EP | claimed |
| JP-61091122-A | — | — | None | — | — | JP | disclosed |
| JP-61093181-A | — | — | None | — | — | JP | disclosed |
| US-8277782-B2 | Antiinflammatory agent, metalloproteinase inhibitor, anti-oxidant and modifier of cell redox status, vitamins, inhibitor of activation of nuclear factor kappa beta | THE PROCTER & GAMBLE COMPANY (US) | 2012-10-02 | — | — | US | disclosed |
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | disclosed |
| EP-1294367-B1 | ORAL COMPOSITIONS COMPRISING HOST-RESPONSE MODULATING AGENT | PROCTER & GAMBLE (US) | 2008-07-16 | — | — | EP | disclosed |
| US-20060193790-A1 | Promoting whole body health | THE PROCTER & GAMBLE COMPANY | 2006-08-31 | — | — | US | disclosed |
| EP-1594873-A1 | PYRROLIDINOHYDROCHINAZOLINES | Boehringer Ingelheim International GmbH (DE) | 2005-11-16 | — | — | EP | disclosed |
| US-20050042283-A1 | Histamine and CCK2/gastrin receptor blockade in the treatment of acid-peptic disease and cancer | UNIVERSITY OF MASSACHUSETTS (US) | 2005-02-24 | — | — | US | disclosed |
| WO-2005007107-A2 | HISTAMINE AND CCK2/GASTRIN RECEPTOR BLOCKADE IN THE TREATMENT OF ACID-PEPTIC DISEASE AND CANCER | UNIVERSITY OF MASSACHUSETTS (US) | 2005-01-27 | — | — | WO | disclosed |
| WO-2004072074-A1 | PYRROLIDINOHYDROCHINAZOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-08-26 | — | — | WO | disclosed |
| EP-1189662-A1 | COMBINATION FOR TREATING WEIGHT GAIN ASSOCIATED WITH ANTIPSYCHOTIC USE COMPRISING AN ATYPICAL ANTIPSYCHOTIC AND AN H2 ANTAGONIST | ELI LILLY AND COMPANY (US) | 2002-03-27 | — | — | EP | disclosed |
| WO-2000074784-A1 | COMBINATION FOR TREATING WEIGHT GAIN ASSOCIATED WITH ANTIPSYCHOTIC USE COMPRISING AN ATYPICAL ANTIPSYCHOTIC AND AN H2 ANTAGONIST | ELI LILLY AND COMPANY (US) | 2000-12-14 | — | — | WO | disclosed |
| EP-0703782-A1 | H2-ANTAGONISTS AS IMMUNE STIMULANTS IN BACTERIAL INFECTIONS OF CATTLE OR SWINE | PFIZER INC. (US) | 1996-04-03 | — | — | EP | disclosed |
| WO-1994028898-A1 | H2-ANTAGONISTS AS IMMUNE STIMULANTS IN BACTERIAL INFECTIONS OF CATTLE OR SWINE | PFIZER INC. (US) | 1994-12-22 | — | — | WO | disclosed |
| US-5364616-A | Use of H-2 antagonists for treatment of gingivitis | THE PROCTER & GAMBLE COMPANY (US) | 1994-11-15 | — | — | US | disclosed |
| EP-0269239-B1 | Processes for 2-(1-pentyl-3-guanidino)-4-(2-methyl-4-imidazolyl)thiazole and the crystalline dihydrochloride trihydrate thereof | PFIZER (US) | 1994-06-08 | — | — | EP | disclosed |
| US-5294433-A | Dentistry | THE PROCTER & GAMBLE COMPANY (US) | 1994-03-15 | — | — | US | disclosed |
| CN-1011196-B | Improved anti-inflammatory pharmaceutical compositions | PFIZER (US) | 1991-01-16 | — | — | CN | disclosed |
| EP-0178121-B1 | IMPROVED FORMULATION OF ANTIINFLAMMATORY DRUGS | PFIZER INC. (US) | 1990-06-13 | — | — | EP | disclosed |
| CN-1008062-B | METHOD FOR PREPARING IMPROVED ANTIINFLAMMATORY SALTS OF PIROXICAM | PFIZER (US) | 1990-05-23 | — | — | CN | disclosed |
| EP-0178822-B1 | 2-GUANIDINO-4-(2-METHYL-4-IMIDAZOLYL)THIAZOLES IN THE TREATMENT OF RHEUMATOID ARTHRITIS | PFIZER INC. (US) | 1990-01-17 | — | — | EP | disclosed |
| EP-0178822-B1 | 2-GUANIDINO-4-(2-METHYL-4-IMIDAZOLYL)THIAZOLES IN THE TREATMENT OF RHEUMATOID ARTHRITIS | PFIZER INC. (US) | 1990-01-17 | — | — | EP | disclosed |
| EP-0138464-B1 | 2-AMINO-5-HYDROXY-4-METHYLPYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1989-11-15 | — | — | EP | disclosed |
| EP-0178124-B1 | IMPROVED ANTIINFLAMMATORY SALTS OF PIROXICAM | PFIZER INC. (US) | 1989-06-21 | — | — | EP | disclosed |
| EP-0178822-A3 | 2-GUANIDINO-4-(2-METHYL-4-IMIDAZOLYL)THIAZOLES IN THE TREATMENT OF RHEUMATOID ARTHRITIS | — | 1988-01-13 | — | — | EP | disclosed |
| EP-0125777-B1 | PROCESS AND INTERMEDIATES FOR PREPARATION OF 4-ACETYL-2-SUBSTITUTED-IMIDAZOLES | PFIZER INC. (US) | 1987-06-24 | — | — | EP | disclosed |
| US-4673677-A | 2-AMINO-5-HYDROXY-4-METHYLPYRIMIDINE | PFIZER INC. (US) | 1987-06-16 | — | — | US | disclosed |
| US-4636498-A | OXICAMS, ANTIULCER, ANTISECRETORY 2-GUANIDINO-4-(4-IMIDAZOLYL) THIAZOLES | PFIZER INC. (US) | 1987-01-13 | — | — | US | disclosed |
| US-4636498-A | OXICAMS, ANTIULCER, ANTISECRETORY 2-GUANIDINO-4-(4-IMIDAZOLYL) THIAZOLES | PFIZER INC. (US) | 1987-01-13 | — | — | US | disclosed |
| US-4632993-A | Process for making 2-guanidino-4-(2-methyl-4-imidazolyl) thiazole dihydrobromide | PFIZER INC. (US) | 1986-12-30 | — | — | US | disclosed |
| US-4591595-A | 2-guanidino-4-(2-methyl-4-imidazolyl)thiazoles in the treatment of rheumatoid arthritis | PFIZER INC. (US) | 1986-05-27 | — | — | US | disclosed |
| US-4591595-A | 2-guanidino-4-(2-methyl-4-imidazolyl)thiazoles in the treatment of rheumatoid arthritis | PFIZER INC. (US) | 1986-05-27 | — | — | US | disclosed |
| US-4591595-A | 2-guanidino-4-(2-methyl-4-imidazolyl)thiazoles in the treatment of rheumatoid arthritis | PFIZER INC. (US) | 1986-05-27 | — | — | US | disclosed |
| US-4590299-A | 2-guanidino-4-heteroarylthiazoles | PFIZER INC. (US) | 1986-05-20 | — | — | US | disclosed |
| JP-S6193181-A | 2-GUANIDINO-4-(2-METHYL-4-IMIDAZOLYL)THIAZOLE HYDRODIBROMIDEAND MANUFACTURE | PFIZER | 1986-05-12 | — | — | JP | disclosed |
| JP-S6191122-A | TREATMENT OF CHRONIC ARTICULAR RHEUMATISM BY 2-GUANIDINO-4-(2-METHYL-4-IMIDAZOLYL)THIAZOLES | PFIZER | 1986-05-09 | — | — | JP | disclosed |
| EP-0178822-A2 | 2-Guanidino-4-(2-methyl-4-imidazolyl)thiazoles in the treatment of rheumatoid arthritis | PFIZER INC. (US) | 1986-04-23 | — | — | EP | disclosed |
| EP-0178822-A2 | 2-Guanidino-4-(2-methyl-4-imidazolyl)thiazoles in the treatment of rheumatoid arthritis | PFIZER INC. (US) | 1986-04-23 | — | — | EP | disclosed |
| EP-0178121-A2 | Improved formulation of antiinflammatory drugs | PFIZER INC. (US) | 1986-04-16 | — | — | EP | disclosed |
| EP-0178121-A2 | Improved formulation of antiinflammatory drugs | PFIZER INC. (US) | 1986-04-16 | — | — | EP | disclosed |
| EP-0178123-A2 | 2-Guanidino-4-(2-methyl-4-imidazolyl)thiazole dihydrobromide and process therefor | PFIZER INC. (US) | 1986-04-16 | — | — | EP | disclosed |
| EP-0178123-A2 | 2-Guanidino-4-(2-methyl-4-imidazolyl)thiazole dihydrobromide and process therefor | PFIZER INC. (US) | 1986-04-16 | — | — | EP | disclosed |
| EP-0178124-A1 | Improved antiinflammatory salts of piroxicam | PFIZER INC. (US) | 1986-04-16 | — | — | EP | disclosed |
| EP-0178124-A1 | Improved antiinflammatory salts of piroxicam | PFIZER INC. (US) | 1986-04-16 | — | — | EP | disclosed |
| US-4567179-A | Antiinflammatory salts of piroxicam | PFIZER, INC. (US) | 1986-01-28 | — | — | US | disclosed |
| US-4567179-A | Antiinflammatory salts of piroxicam | PFIZER, INC. (US) | 1986-01-28 | — | — | US | disclosed |
| US-4554276-A | ENZYME INHIBITORS, ANTIULCER AGENTS | PFIZER INC. (US) | 1985-11-19 | — | — | US | disclosed |
| EP-0138464-A2 | 2-Amino-5-hydroxy-4-methylpyrimidine derivatives | PFIZER INC. (US) | 1985-04-24 | — | — | EP | disclosed |
| US-4510313-A | 2-Guanidino-4-heteroarylthiazoles | PFIZER INC. (US) | 1985-04-09 | — | — | US | disclosed |
| EP-0050458-B1 | 2-GUANIDINO-4-HETEROARYLTHIAZOLES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PFIZER INC. (US) | 1985-01-02 | — | — | EP | disclosed |
| US-4482723-A | FORM 3-HALO-4,4-DIALKOXY-2-ALKANONE AND AN AMIDINE | PFIZER INC. (US) | 1984-11-13 | — | — | US | disclosed |
| US-4452987-A | Haloacetyl imidazoles | PFIZER INC. (US) | 1984-06-05 | — | — | US | disclosed |
| US-4374843-A | 2-Guanidino-4-heteroarylthiazoles | PFIZER INC. (US) | 1983-02-22 | — | — | US | disclosed |
| EP-0050458-A2 | 2-Guanidino-4-heteroarylthiazoles and pharmaceutical compositions containing them | PFIZER INC. (US) | 1982-04-28 | — | — | EP | disclosed |
| JP-S06191122-A | — | — | 0001-01-01 | — | — | JP | disclosed |
| JP-S06191122-A | — | — | 0001-01-01 | — | — | JP | disclosed |
| JP-S06193181-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | GRN, MAPT, GUCY1B1 | ATP4A 996/4885ATP4B 1107/4885ABL1 4507/4885 |
| US-20060193790-A1 | Promoting whole body health | IFNG, TNF, TLR6 | ATP4A 2406/4885ATP4B 3360/4885ABL1 4482/4885 |
| US-20050042283-A1 | Histamine and CCK2/gastrin receptor blockade in the treatment of acid-peptic disease and cancer | HRH2, CCKBR, GRPR | ATP4A 1168/4885ATP4B 1661/4885ABL1 867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.